Basic	0	5	B-Gene_or_gene_product
fibroblast	6	16	I-Gene_or_gene_product
growth	17	23	I-Gene_or_gene_product
factor	24	30	I-Gene_or_gene_product
:	30	31	O
a	32	33	O
missing	34	41	O
link	42	46	O
between	47	54	O
collagen	55	63	B-Gene_or_gene_product
VII	64	67	I-Gene_or_gene_product
,	67	68	O
increased	69	78	O
collagenase	79	90	B-Gene_or_gene_product
,	90	91	O
and	92	95	O
squamous	96	104	B-Pathological_formation
cell	105	109	I-Pathological_formation
carcinoma	110	119	I-Pathological_formation
in	120	122	O
recessive	123	132	O
dystrophic	133	143	O
epidermolysis	144	157	O
bullosa	158	165	O
.	165	166	O

BACKGROUND	168	178	O
:	178	179	O
Patients	180	188	B-Organism
with	189	193	O
recessive	194	203	O
dystrophic	204	214	O
epidermolysis	215	228	O
bullosa	229	236	O
(	237	238	O
RDEB	238	242	O
)	242	243	O
have	244	248	O
deficiencies	249	261	O
of	262	264	O
collagen	265	273	B-Gene_or_gene_product
type	274	278	I-Gene_or_gene_product
VII	279	282	I-Gene_or_gene_product
and	283	286	O
have	287	291	O
elevated	292	300	O
levels	301	307	O
of	308	310	O
fibroblast	311	321	B-Gene_or_gene_product
collagenase	322	333	I-Gene_or_gene_product
,	333	334	O
and	335	338	O
a	339	340	O
greatly	341	348	O
increased	349	358	O
risk	359	363	O
of	364	366	O
cutaneous	367	376	B-Pathological_formation
squamous	377	385	I-Pathological_formation
cell	386	390	I-Pathological_formation
carcinoma	391	400	I-Pathological_formation
.	400	401	O

Patients	402	410	B-Organism
with	411	415	O
other	416	421	O
genetic	422	429	O
blistering	430	440	O
disorders	441	450	O
do	451	453	O
not	454	457	O
have	458	462	O
elevated	463	471	O
collagenase	472	483	B-Gene_or_gene_product
or	484	486	O
an	487	489	O
increased	490	499	O
risk	500	504	O
of	505	507	O
squamous	508	516	B-Pathological_formation
cell	517	521	I-Pathological_formation
carcinoma	522	531	I-Pathological_formation
,	531	532	O
despite	533	540	O
chronic	541	548	O
wounding	549	557	O
.	557	558	O

The	559	562	O
connection	563	573	O
between	574	581	O
collagen	582	590	B-Gene_or_gene_product
type	591	595	I-Gene_or_gene_product
VII	596	599	I-Gene_or_gene_product
deficiency	600	610	O
,	610	611	O
increased	612	621	O
collagenase	622	633	B-Gene_or_gene_product
,	633	634	O
and	635	638	O
squamous	639	647	B-Pathological_formation
cell	648	652	I-Pathological_formation
carcinoma	653	662	I-Pathological_formation
is	663	665	O
not	666	669	O
understood	670	680	O
.	680	681	O

MATERIALS	682	691	O
AND	692	695	O
METHODS	696	703	O
:	703	704	O
Urine	705	710	B-Organism_substance
from	711	715	O
81	716	718	O
patients	719	727	B-Organism
with	728	732	O
RDEB	733	737	O
(	738	739	O
39	739	741	O
patients	742	750	B-Organism
)	750	751	O
,	751	752	O
junctional	753	763	O
epidermolysis	764	777	O
bullosa	778	785	O
(	786	787	O
JEB	787	790	O
;	790	791	O
12	792	794	O
patients	795	803	B-Organism
)	803	804	O
,	804	805	O
and	806	809	O
epidermolysis	810	823	O
bullosa	824	831	O
simplex	832	839	O
(	840	841	O
EBS	841	844	O
;	844	845	O
30	846	848	O
patients	849	857	B-Organism
)	857	858	O
,	858	859	O
as	860	862	O
well	863	867	O
as	868	870	O
unaffected	871	881	O
family	882	888	O
members	889	896	O
of	897	899	O
RDEB	900	904	O
patients	905	913	B-Organism
(	914	915	O
33	915	917	O
patients	918	926	B-Organism
)	926	927	O
,	927	928	O
was	929	932	O
tested	933	939	O
for	940	943	O
the	944	947	O
presence	948	956	O
of	957	959	O
basic	960	965	B-Gene_or_gene_product
fibroblast	966	976	I-Gene_or_gene_product
growth	977	983	I-Gene_or_gene_product
factor	984	990	I-Gene_or_gene_product
(	991	992	O
bFGF	992	996	B-Gene_or_gene_product
)	996	997	O
using	998	1003	O
a	1004	1005	O
sensitive	1006	1015	O
radioimmunoassay	1016	1032	O
.	1032	1033	O

These	1034	1039	O
patients	1040	1048	B-Organism
included	1049	1057	O
many	1058	1062	O
who	1063	1066	O
were	1067	1071	O
enrolled	1072	1080	O
in	1081	1083	O
the	1084	1087	O
Epidermolysis	1088	1101	O
Bullosa	1102	1109	O
Registry	1110	1118	O
and	1119	1122	O
others	1123	1129	O
who	1130	1133	O
were	1134	1138	O
referred	1139	1147	O
by	1148	1150	O
their	1151	1156	O
physicians	1157	1167	O
.	1167	1168	O

RESULTS	1169	1176	O
:	1176	1177	O
Fifty	1178	1183	O
-	1183	1184	O
one	1184	1187	O
percent	1188	1195	O
of	1196	1198	O
patients	1199	1207	B-Organism
with	1208	1212	O
RDEB	1213	1217	O
had	1218	1221	O
elevated	1222	1230	O
levels	1231	1237	O
(	1238	1239	O
greater	1240	1247	O
than	1248	1252	O
5000	1254	1258	O
pg	1259	1261	O
/	1261	1262	O
g	1262	1263	O
)	1263	1264	O
of	1265	1267	O
urinary	1268	1275	B-Organism_substance
bFGF	1276	1280	B-Gene_or_gene_product
.	1280	1281	O

In	1282	1284	O
contrast	1285	1293	O
,	1293	1294	O
none	1295	1299	O
of	1300	1302	O
the	1303	1306	O
patients	1307	1315	B-Organism
with	1316	1320	O
JEB	1321	1324	O
had	1325	1328	O
elevated	1329	1337	O
levels	1338	1344	O
of	1345	1347	O
bFGF	1348	1352	B-Gene_or_gene_product
.	1352	1353	O

Twenty	1354	1360	O
-	1360	1361	O
one	1361	1364	O
percent	1365	1372	O
of	1373	1375	O
clinically	1376	1386	O
unaffected	1387	1397	O
family	1398	1404	O
members	1405	1412	O
had	1413	1416	O
elevated	1417	1425	O
levels	1426	1432	O
of	1433	1435	O
bFGF	1436	1440	B-Gene_or_gene_product
,	1440	1441	O
and	1442	1445	O
13	1446	1448	O
%	1448	1449	O
of	1450	1452	O
patients	1453	1461	B-Organism
with	1462	1466	O
EBS	1467	1470	O
had	1471	1474	O
elevated	1475	1483	O
levels	1484	1490	O
of	1491	1493	O
bFGF	1494	1498	B-Gene_or_gene_product
.	1498	1499	O

The	1500	1503	O
frequency	1504	1513	O
of	1514	1516	O
elevated	1517	1525	O
bFGF	1526	1530	B-Gene_or_gene_product
values	1531	1537	O
among	1538	1543	O
all	1544	1547	O
groups	1548	1554	O
was	1555	1558	O
statistically	1559	1572	O
significant	1573	1584	O
(	1585	1586	O
p	1586	1587	O
=	1588	1589	O
0	1590	1591	O
.	1591	1592	O
002	1592	1595	O
)	1595	1596	O
,	1596	1597	O
and	1598	1601	O
the	1602	1605	O
levels	1606	1612	O
of	1613	1615	O
bFGF	1616	1620	B-Gene_or_gene_product
in	1621	1623	O
RDEB	1624	1628	O
patients	1629	1637	B-Organism
were	1638	1642	O
significantly	1643	1656	O
elevated	1657	1665	O
compared	1666	1674	O
with	1675	1679	O
those	1680	1685	O
of	1686	1688	O
other	1689	1694	O
groups	1695	1701	O
(	1702	1703	O
p	1703	1704	O
less	1706	1710	O
than	1711	1715	O
0	1717	1718	O
.	1718	1719	O
05	1719	1721	O
)	1721	1722	O
.	1722	1723	O

CONCLUSIONS	1724	1735	O
:	1735	1736	O
We	1737	1739	O
have	1740	1744	O
found	1745	1750	O
that	1751	1755	O
patients	1756	1764	B-Organism
with	1765	1769	O
RDEB	1770	1774	O
have	1775	1779	O
elevated	1780	1788	O
levels	1789	1795	O
of	1796	1798	O
bFGF	1799	1803	B-Gene_or_gene_product
,	1803	1804	O
which	1805	1810	O
may	1811	1814	O
contribute	1815	1825	O
to	1826	1828	O
increased	1829	1838	O
fibroblast	1839	1849	B-Gene_or_gene_product
collagenase	1850	1861	I-Gene_or_gene_product
and	1862	1865	O
the	1866	1869	O
development	1870	1881	O
of	1882	1884	O
squamous	1885	1893	B-Pathological_formation
cell	1894	1898	I-Pathological_formation
carcinoma	1899	1908	I-Pathological_formation
.	1908	1909	O

These	1910	1915	O
results	1916	1923	O
suggest	1924	1931	O
a	1932	1933	O
novel	1934	1939	O
treatment	1940	1949	O
for	1950	1953	O
RDEB	1954	1958	O
,	1958	1959	O
namely	1960	1966	O
,	1966	1967	O
angiogenesis	1968	1980	O
inhibitors	1981	1991	O
,	1991	1992	O
which	1993	1998	O
may	1999	2002	O
antagonize	2003	2013	O
the	2014	2017	O
effects	2018	2025	O
of	2026	2028	O
bFGF	2029	2033	B-Gene_or_gene_product
in	2034	2036	O
this	2037	2041	O
disorder	2042	2050	O
.	2050	2051	O

There	2052	2057	O
are	2058	2061	O
currently	2062	2071	O
no	2072	2074	O
other	2075	2080	O
means	2081	2086	O
of	2087	2089	O
treatment	2090	2099	O
for	2100	2103	O
this	2104	2108	O
disorder	2109	2117	O
,	2117	2118	O
which	2119	2124	O
has	2125	2128	O
a	2129	2130	O
high	2131	2135	O
morbidity	2136	2145	O
and	2146	2149	O
mortality	2150	2159	O
rate	2160	2164	O
.	2164	2165	O

